Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
PA8 | Frankfurt | EUR | Delayed | |
0NF3 | London | EUR | Real-time | |
PA8 | TradeGate | EUR | Delayed |
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. The company’s lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.
Name | Age | Since | Title |
---|---|---|---|
Markus Leyck Dieken | - | 2019 | Member of Supervisory Board |
Hans Christoph Tanner | 71 | 2017 | Member of Supervisory Board |
Karin Louise Dorrepaal | 61 | 2012 | Independent Vice Chairman of Supervisory Board |
Michael Schlenk | - | 2022 | Chairman of the Supervisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review